Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The Sackler family owns Purdue Pharma, the privately held drug company that has made billions from OxyContin, and Sacklers hold most of the seats on the board. Members of the family have been accused in a case brought by the state of Massachusetts of deceiving patients and doctors about the drug's risks as deaths mounted. And documents recently released in the case shine new light on former Purdue Pharma President Richard Sackler's role in the aggressive marketing of the powerful opioid. As the allegations mount, family members who made their fortunes well before OxyContin even went on the market have sought to distance themselves from their relatives. At the same time, activists have called on institutions to cut ties with the Sacklers, staging protests at museums that have received millions in donations. "The Sackler name is becoming synonymous with the opioid epidemic, and it is damning for these institutions to have their name up," said Nan Goldin, a photographer whose works have been displayed at Harvard's Arthur M. Sackler Museum and at New York's Metropolitan Museum of Art, which has a Sackler Wing. Lost in the outrage: One of the most generous and best known of the Sacklers died in 1987, nearly a decade before OxyContin was released. Arthur M. Sackler made his money from medical research, medical advertising and trade publications. His younger brothers, Raymond and Mortimer, bought out his stake after he died. Arthur Sackler's name is on a gallery at the Smithsonian, a wing of galleries at London's Royal Academy of Arts and a museum at Beijing's Peking University. The Sackler Wing at the Met, which houses the celebrated Temple of Dendur from ancient Egypt, was funded by all three brothers. Richard has likewise donated heavily to various institutions. After a federal investigation, Purdue Pharma and three executives none of them Sacklers pleaded guilty in 2007 and agreed to pay more than $600 million for misleading the public about the risks of OxyContin. The Stamford, Connecticut, company has also been hit with a multitude of lawsuits over its role in the opioid crisis that killed more than 47,000 people in 2017 alone. Arthur's nephew, Richard Sackler, who became president of Purdue Pharma in 1999 and remains on the board, is at the center of the litigation. He and other current and former executives have been accused of hiding the dangers of the drug from doctors and patients, encouraging physicians to prescribe more of the highest doses and minimizing the abuse crisis as it was unfolding. "This is not too bad. It could have been far worse," he wrote to Purdue Pharma executives in 2001 after a federal prosecutor reported that 59 people in one state had died from OxyContin, according to documents released this week in the Massachusetts case. At the launch party for OxyContin in 1996, Richard Sackler boasted the drug would bring a "blizzard of prescriptions that will bury the competition," the documents say. Years later, they say, he sought to shift blame onto drug users themselves, recommending the company "hammer on the abusers in every way possible." "Richard followed that strategy for the rest of his career: collect millions from selling addictive drugs, and blame the terrible consequences on the people who became addicted," attorneys in Massachusetts Attorney General Maura Healey's office wrote. "By their misconduct, the Sacklers have hammered Massachusetts families in every way possible. And the stigma they used as a weapon made the crisis worse." A spokesman for Richard Sackler's family referred questions about the lawsuit to the company. Purdue Pharma said in a statement that Massachusetts' case the first one brought by a state to personally name members of the Sackler family is "littered with biased and inaccurate characterizations." The company said it will "aggressively defend against these misleading allegations." Arthur Sackler's widow and children insist that they never financially benefited from the sale of OxyContin. "It is a gross injustice to connect Arthur to the opioid crisis some 30 years after his death when he had nothing to do with it," Dame Jillian Sackler said in a statement. "It denies the many important contributions he made working to improve world health and to build cultural bridges between peoples." But activists have made no distinction between Arthur and his relatives. In July, dozens of activists led by Goldin held a protest inside the Arthur M. Sackler Museum at Harvard, scattering pill bottles and holding banners that read "SHAME ON SACKLER." Similar demonstrations have been held at the Met and the Smithsonian. Goldin, who was addicted OxyContin for years, said that getting the institutions to act will be difficult. "Who is going to turn down the money? They offer millions to these institutions, and the board members are not necessarily committed to action, so it's going to take a lot," she said. A Met spokesman said that the Sackler family's support began decades before the opioid crisis, but that the museum will be examining its gift acceptance policies. The Guggenheim, home to the Sackler Center for Arts Education, had no comment. A Harvard spokesman said in an email that Arthur Sackler's donation in 1982 paid for the construction of the building that originally housed the museum but that his foundation does not fund the museum. ___ Associated Press reporter Verena Dobnik contributed to this report from New York. ___ Follow Alanna Durkin Richer at http://www.twitter.com/aedurkinricher
Example Output: Opioid crisis brings unwanted attention to wealthy family.

Example Input: The system preserves the most amount of natural bone, making it a less invasive way to treat diseased joints. Kalamazoo, Michigan-based Stryker, one of the top makers of reconstructive implants, said its system, called Triathlon PKR, is beneficial because it allows surgeons to provide personalized solutions by only shaving off diseased parts of the knee rather than replacing larger parts of it, or the entire knee joint. Partial knee resurfacing requires less operating time than total keep replacements and there is a shorter recovery period, with some patients leaving the hospital in less than 24 hours, Stryker said. Because less bone is removed, there is often less trauma to soft tissue during surgery, which may leave the patient with a more natural feeling knee than with a total knee replacement, the company added.
Example Output: Stryker launches partial knee resurfacing systems.

Example Input: The story doesn't mention costs. However, the piece is clear that this is early-stage research that might not pan out, so we think it's acceptable that there's no cost discussion. The story suggests that treatment withaducanumab results in "striking," "dramatic" and "remarkable" reductions in amyloid plaques in the brain. But it doesn't quantify what that means. How many patients saw their plaque levels go down? By how much? Is the reduction bigger than what has been seen with other experimental Alzheimer's drugs? These details would've been helpful. The story is clear that the drug's effects on amyloid plaque are accompanied by potential harms: But there's a downside. The process of removing plaque sometimes causes fluid to build up in the brain. In rare cases, it can also cause bleeding. These side effects are known as amyloid-related imaging abnormalities, or ARIA. We're also told that about 20 participants dropped out of because of adverse effects. The story cautions that these results are from small, early studies and that plaque reduction is a proxy for outcomes that really matter to patients. But it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says. And unlike many stories we've seen that discuss therapies to reduce amyloid, this piece acknowledges that we don't whether amyloid is actually a cause of Alzheimer's symptoms or perhaps an effect of the disease. If aducanumab works in larger studies, it could help settle a long-running debate about whether amyloid is really the root cause of Alzheimer's. This idea is known as the amyloid hypothesis. And large studies showing that removing amyloid can preserve memory and thinking "would go a long way toward validating the amyloid hypothesis," Sandrock says. We do wish the story had noted that about one third of patients in all groups dropped out before completion of the study, which could impact the quality of the overall findings. The story doesn't disease monger, but it also doesn't explain what Alzheimer's is or give any sense as to the impact of the disease. We'll rate this Not Applicable. The story quotes an official from Biogen (which makes the experimental drug) and the author of an accompanying editorial. But we don't hear from any truly independent sources in the story. The editorialist, Dr. Eric Reiman, is said to be theexecutive director of the Banner Alzheimer's Institute in Phoenix. It doesn't explain that the Banner Institute is leading Alzheimer's Prevention Initiative, an effort to postpone and prevent the disease before it starts. The initiative partners with a number of drug companies, including Roche, Amgen, Genentech, Novartis, on its studies. These relationships merited a mention in the story. The story is clear that there are no drugs that treat the underlying cause of Alzheimer's. It links to a story about a competing amyloid-reducing drug that failed to produce any benefit in a large clinical trial. We did want to know: Are there any older drugs that have been tried for this? Were they equally optimistic when they were first introduced? Putting them into perspective would help as it seems there were prior drugs that were hyped to prevent or slow the progression of ADbut subsequently didn't pan out. The story calls the drug experimental and says that it will take several years for larger studies to report results. It's apparent that the drug won't be available outside of a research study any time soon. The story establishes what appears to be novel about this drug compared with others that reduce amyloid plaques. One is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid. But while the story is clear that the new paper is presenting details of research first reported last year, it doesn't explain why the results are now "remarkable" whereas last year they were considered "disappointing,""mixed"and a "setback." We'll rate this a borderline Satisfactory. The story includes original reporting and clearly goes beyond any news release.
Example Output:
Test Of Experimental Alzheimer's Drug Finds Progress Against Brain Plaques